JP2010524963A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524963A5
JP2010524963A5 JP2010504247A JP2010504247A JP2010524963A5 JP 2010524963 A5 JP2010524963 A5 JP 2010524963A5 JP 2010504247 A JP2010504247 A JP 2010504247A JP 2010504247 A JP2010504247 A JP 2010504247A JP 2010524963 A5 JP2010524963 A5 JP 2010524963A5
Authority
JP
Japan
Prior art keywords
ion
pairing agent
lipoic acid
pharmaceutical formulation
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524963A (ja
JP5480804B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/060650 external-priority patent/WO2008131114A2/en
Publication of JP2010524963A publication Critical patent/JP2010524963A/ja
Publication of JP2010524963A5 publication Critical patent/JP2010524963A5/ja
Application granted granted Critical
Publication of JP5480804B2 publication Critical patent/JP5480804B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504247A 2007-04-18 2008-04-17 リポ酸誘導体を含有する医薬製剤 Expired - Fee Related JP5480804B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91260507P 2007-04-18 2007-04-18
US60/912,605 2007-04-18
PCT/US2008/060650 WO2008131114A2 (en) 2007-04-18 2008-04-17 Pharmaceutical formulations containing lipoic acid derivatives

Publications (3)

Publication Number Publication Date
JP2010524963A JP2010524963A (ja) 2010-07-22
JP2010524963A5 true JP2010524963A5 (OSRAM) 2012-05-31
JP5480804B2 JP5480804B2 (ja) 2014-04-23

Family

ID=39872894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504247A Expired - Fee Related JP5480804B2 (ja) 2007-04-18 2008-04-17 リポ酸誘導体を含有する医薬製剤

Country Status (19)

Country Link
US (4) US20080262077A1 (OSRAM)
EP (1) EP2144609B1 (OSRAM)
JP (1) JP5480804B2 (OSRAM)
KR (1) KR101539785B1 (OSRAM)
CN (1) CN101820875B (OSRAM)
AR (1) AR067309A1 (OSRAM)
AU (1) AU2008242827B2 (OSRAM)
BR (1) BRPI0810439B1 (OSRAM)
CA (1) CA2684479C (OSRAM)
CL (1) CL2008001124A1 (OSRAM)
ES (1) ES2528414T3 (OSRAM)
IL (1) IL201581A (OSRAM)
MX (1) MX2009011165A (OSRAM)
NZ (1) NZ580973A (OSRAM)
PL (1) PL2144609T3 (OSRAM)
PT (1) PT2144609E (OSRAM)
SA (1) SA08290240B1 (OSRAM)
TW (1) TWI459944B (OSRAM)
WO (1) WO2008131114A2 (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101644192B1 (ko) * 2007-04-18 2016-07-29 코너스톤 파마슈티칼스, 인크. 리포산 유도체
MX2009011165A (es) 2007-04-18 2009-12-09 Cornerstone Pharmaceuticals In Formulaciones farmaceuticas que contienen derivados del acido lipoico.
US8263653B2 (en) 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
BRPI0821176A2 (pt) * 2008-03-04 2015-10-06 Robert Rodriguez modulador do estado de fosforilação de pelo menos um complexo de enzimas, método para modular o complexo de pdh em um paciente que apresenta uma doença, condição, ou síndrome e método pra diagnosticar e predizer benefício em um paciente que apresenta sintomas de uma doença, condição, ou síndrome causada por uma alteração da estrutura e/ou da atividade do complexo de pdh
CN102056605A (zh) * 2008-04-04 2011-05-11 罗伯特·绍尔 药物组合物
CA2745383A1 (en) * 2008-12-01 2010-06-10 In Vasc Therapeutics, Inc. Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
WO2010110771A2 (en) * 2009-03-25 2010-09-30 Frank Gibson Substituted thiol-containing alkyl fatty acids and process for synthesizing derivatives thereof
CA2782676C (en) 2009-12-01 2021-06-15 Shire Human Genetic Therapies, Inc. Pharmaceutical compositions for intracellular delivery of nucleic acids and proteins and uses thereof for treatment of ureca cycle metabolic disorders
WO2011143590A1 (en) * 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011143593A1 (en) * 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
CA3107288A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
CN102657606B (zh) * 2012-05-25 2014-01-01 江苏神龙药业有限公司 一种供静脉给药用的硫辛酸注射液
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
US20150322103A1 (en) * 2012-12-19 2015-11-12 Cornerstone Pharmaceuticals, Inc. Pharmaceutical compounds
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
MX365409B (es) 2013-03-14 2019-05-31 Shire Human Genetic Therapies Composiciones de ácido ribonucleico mensajero del regulador transmembrana de fibrosis quística y métodos y usos relacionados.
CN103360437B (zh) * 2013-04-27 2015-10-21 江苏教育学院 一种硫辛酸糖类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN103497344B (zh) * 2013-09-25 2015-09-23 深圳先进技术研究院 用于负载贵金属颗粒的纳米凝胶及其制备方法与应用
EP3060303B1 (en) 2013-10-22 2018-11-14 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
KR20250005450A (ko) 2014-04-25 2025-01-09 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna 의 정제 방법
WO2015195070A1 (en) * 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
AU2014398233B2 (en) * 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3841208A1 (en) 2018-08-24 2021-06-30 Translate Bio, Inc. Methods for purification of messenger rna
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
TW202114651A (zh) * 2019-08-16 2021-04-16 美商拉斐爾製藥公司 用於治療癌症之方法及含有４，６—雙（苄硫基）己酸之藥物組成物
US20230092232A1 (en) * 2020-02-28 2023-03-23 University Of Florida Research Foundation, Incorporated Compounds that modulate anti-tumor immunity and methods of doing the same
JP2023549086A (ja) * 2020-11-03 2023-11-22 コーナーストーン ファーマシューティカルズ，インコーポレーテッド デビミスタットを使用して胆道癌を治療するための治療法及び組成物
CN119770650A (zh) * 2025-01-09 2025-04-08 华中科技大学 一种硫辛酸-胆碱离子液体溶液及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2805251A (en) * 1953-07-22 1957-09-03 Ethyl Corp Preparation of aryloxyaliphatic acids and salts thereof
GB758897A (en) 1953-10-19 1956-10-10 Merck & Co Inc Thio-substituted aliphatic carboxylic acids and their preparation
US3002011A (en) * 1953-12-04 1961-09-26 Merck & Co Inc Intermediates and processes for producing alpha-lipoic acid
US2809978A (en) * 1953-12-04 1957-10-15 Merck & Co Inc Intermediates useful in the synthesis of alpha-lipoic acid
US2980716A (en) * 1954-06-11 1961-04-18 Research Corp Method for preparing 6, 8-dihalooctanoic esters
US2975198A (en) * 1954-07-08 1961-03-14 Research Corp Lipoic acid intermediates
US2852531A (en) * 1954-09-24 1958-09-16 Merck & Co Inc Tris-(2-tetrahydropyranyl) esters of 6, 8-bis (hydrocarbonmercapto)-4, 4-dicarboxy-5-ocaprylic acid and preparation thereof
US2875238A (en) * 1957-02-19 1959-02-24 Merck & Co Inc Intermediates useful in the synthesis of alpha-lipoic acid
US2875239A (en) * 1957-02-19 1959-02-24 Merck & Co Inc Intermediates useful in the synthesis of alpha-lipoic acid
US2985685A (en) * 1959-01-26 1961-05-23 American Cyanamid Co Alkanolamine aluminates as catalysts for ester redistribution
US3453312A (en) * 1966-04-27 1969-07-01 Merck & Co Inc (beta - (substituted-thio) - acylphenoxy)-alkanoic acids and (beta-(substitutedthio) acylphenylmercapto) alkanoic acids and derivatives thereof
US3345368A (en) * 1967-02-15 1967-10-03 American Cyanamid Co Substituted 7-acetylamino cephalosporanic acids
US3881017A (en) * 1973-05-18 1975-04-29 Ciba Geigy Corp 9-Thiaprostaglandin compositions
DE2422498A1 (de) * 1973-05-18 1974-12-05 Ciba Geigy Ag Neue thiaprostaglandine und verfahren zu ihrer herstellung
JPS5323539Y2 (OSRAM) * 1973-11-30 1978-06-17
DE3512911A1 (de) * 1985-04-11 1986-10-16 Degussa Ag, 6000 Frankfurt Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure)
US5344941A (en) * 1986-09-03 1994-09-06 Samour Carlos M Water soluble salts of thionaphthene-2-carboxylic acid
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
US5463093A (en) * 1993-11-26 1995-10-31 Garnett; Merrill Palladium complexes and methods for using same in the treatment of tumors or Psoriasis
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
EP1486495B1 (en) * 1998-10-26 2009-12-09 The Research Foundation of State University of New York Salts of lipoic acid derivatives and their use in treatment of disease
US7320797B2 (en) * 2003-08-29 2008-01-22 Bioderm Research Antiaging cosmetic delivery systems
JP2007077066A (ja) * 2005-09-14 2007-03-29 Shiseido Co Ltd 不全角化抑制剤、毛穴縮小剤
US20090036356A1 (en) * 2006-03-06 2009-02-05 Avestha Gengraine Technologies Pvt. Ltd. Octanoic acid derivatives as dipeptidyl peptidase inhibitors
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
MX2009011165A (es) 2007-04-18 2009-12-09 Cornerstone Pharmaceuticals In Formulaciones farmaceuticas que contienen derivados del acido lipoico.
KR101644192B1 (ko) * 2007-04-18 2016-07-29 코너스톤 파마슈티칼스, 인크. 리포산 유도체

Similar Documents

Publication Publication Date Title
JP2010524963A5 (OSRAM)
KR101539785B1 (ko) 리포산 유도체를 함유하는 약제학적 제형
JPWO2020081938A5 (OSRAM)
ES2381672T3 (es) Preparación en solución acuosa que comprende un antibiótico aminoglicósido y bromfenaco
JP7764041B2 (ja) 脳腫瘍における改善された血液脳関門浸透性及び滞留性を備えた、スケーラブルなチロインテグリンアンタゴニストの組成物
JP2020508985A (ja) 治療用デンドリマー
JP2015512413A5 (OSRAM)
JP2010505865A5 (OSRAM)
JP2003306481A5 (OSRAM)
JP2007505044A5 (OSRAM)
TW201139421A (en) Novel ep4 agonist
KR20090040354A (ko) 방사선 보호 α,β 불포화 아릴설폰 제형
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
RU2010124422A (ru) Производные диоксоантрацен сульфоната
US10358454B2 (en) Marinopyrrole derivatives and methods of making and using same
WO2011136631A1 (es) N6 -(ferrocenmetil)quinazolin-2,4,6-triamina (h2), sus derivados y profarmacos, como agentes antimicrobianos antiparasitarios, antiprotozoarios y antileishmanias
CN109152750B (zh) 用于增殖性疾病的组合疗法
US20080293648A1 (en) Compositions and Methods for Cancer Treatment
CN110958998B (zh) 毛兰素衍生物和使用毛兰素衍生物的方法
WO2019195207A1 (en) Light-activated cannabinoid compounds and methods of use thereof
TWI694838B (zh) 用於疏水性藥物傳送的新穎以聚合物爲基礎的增溶物
ES2965179T3 (es) Derivado polimérico soluble en agua de venetoclax
JP2018525353A5 (OSRAM)
KR20170091610A (ko) 신규 peg 유도체
US20240109934A1 (en) Antibiotics with improved drug resistance profile